PR Newswire Clinical TrialsOriginal article
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Phase 3positiveetentamigPositive
AI Analysis
Summary
AbbVie announced positive Phase 3 CERVINO results for etentamig in relapsed/refractory multiple myeloma, meeting dual primary endpoints of ORR and PFS. The company will present these results and additional portfolio data at the 2026 International Myeloma Society Meeting.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 CERVINO study met dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma
Importance:7/10
Sentiment:
0.75
multiple myelomaPhase 3 dataetentamigCERVINO trialIMS 2026
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 17, 2026 12:30 PM